In a filing, Neumora Therapeutics Inc revealed its Director Fust Matthew K unloaded Company’s shares for reported $0.24 million on Oct 18 ’24. In the deal valued at $17.03 per share,14,049 shares were sold. As a result of this transaction, Fust Matthew K now holds 20,100 shares worth roughly $51858.0.
Then, Fust Matthew K sold 7,739 shares, generating $131,643 in total proceeds. Upon selling the shares at $17.01, the Director now owns 20,100 shares.
Before that, Fust Matthew K bought 14,049 shares. Neumora Therapeutics Inc shares valued at $239,319 were divested by the Director at a price of $17.03 per share.
RBC Capital Mkts downgraded its Neumora Therapeutics Inc [NMRA] rating to a Sector perform from a an Outperform in a research note published on January 02, 2025; the price target was decreased to $4 from $29. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in early November from “an Overweight” to “a Neutral”. H.C. Wainwright began covering NMRA with “Buy” recommendation on October 01, 2024. Needham started covering the stock on July 22, 2024. It rated NMRA as “a Buy”.
Price Performance Review of NMRA
On Tuesday, Neumora Therapeutics Inc [NASDAQ:NMRA] saw its stock jump 4.03% to $2.58. Over the last five days, the stock has lost -76.67%. Neumora Therapeutics Inc shares have fallen nearly -75.66% since the year began. Nevertheless, the stocks have fallen -83.81% over the past one year. While a 52-week high of $21.00 was reached on 01/07/25, a 52-week low of $1.83 was recorded on 01/02/25. SMA at 50 days reached $10.20, while 200 days put it at $11.20.
Levels Of Support And Resistance For NMRA Stock
The 24-hour chart illustrates a support level at 2.43, which if violated will result in even more drops to 2.29. On the upside, there is a resistance level at 2.79. A further resistance level may holdings at 3.01. The Relative Strength Index (RSI) on the 14-day chart is 20.14, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -6.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.30%. Stochastics %K at 5.95% indicates the stock is a buying.
How much short interest is there in Neumora Therapeutics Inc?
A steep rise in short interest was recorded in Neumora Therapeutics Inc stocks on 2024-12-13, growing by 1.02 million shares to a total of 10.83 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 9.81 million shares. There was a rise of 9.41%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 08, 2024 when Mizuho began covering the stock and recommended ‘”an Outperform”‘ rating along with a $20 price target.
